Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$1.78 ▼ -0.08
(-4.30%)
MKT CAP: $106.9M • VOL: 520.2K
52W L $2 52W H $5
ROARABLE / RQD
C- • 59/100
PIOTROSKI
5 / 9
BDTX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $12.5M | -$78.8M | -$86.5M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | $22.37B | -$69.68B | -$82.4M |
| EBITDA (Normalized) | — | -$78.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $29.6M | -$62.3M | -$66.7M |
| Capital Expenditures (CapEx) | — | $0 | — |
| Free Cash Flow (FCF) | $29.6M | -$62.3M | -$66.7M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | 10.8% | -45.0% | — |
| Cash & Short-Term Equivalents | $21.0M | $36.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $112.2M | $83.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BDTX.